IL220812A0 - Compounds and methods - Google Patents
Compounds and methodsInfo
- Publication number
- IL220812A0 IL220812A0 IL220812A IL22081212A IL220812A0 IL 220812 A0 IL220812 A0 IL 220812A0 IL 220812 A IL220812 A IL 220812A IL 22081212 A IL22081212 A IL 22081212A IL 220812 A0 IL220812 A0 IL 220812A0
- Authority
- IL
- Israel
- Prior art keywords
- compounds
- methods
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Cardiology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cephalosporin Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29463710P | 2010-01-13 | 2010-01-13 | |
| PCT/US2011/020798 WO2011088027A1 (en) | 2010-01-13 | 2011-01-11 | Compounds and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL220812A0 true IL220812A0 (en) | 2012-08-30 |
Family
ID=44304601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL220812A IL220812A0 (en) | 2010-01-13 | 2012-07-05 | Compounds and methods |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20120329784A1 (enExample) |
| EP (1) | EP2523559A4 (enExample) |
| JP (1) | JP2013517273A (enExample) |
| KR (1) | KR20120114355A (enExample) |
| CN (1) | CN102791131A (enExample) |
| AU (1) | AU2011205485B2 (enExample) |
| BR (1) | BR112012017277A2 (enExample) |
| CA (1) | CA2786999A1 (enExample) |
| EA (1) | EA201290642A1 (enExample) |
| IL (1) | IL220812A0 (enExample) |
| MX (1) | MX2012008141A (enExample) |
| SG (1) | SG182351A1 (enExample) |
| WO (1) | WO2011088027A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013164323A1 (en) * | 2012-05-03 | 2013-11-07 | F. Hoffmann-La Roche Ag | Pyrazole aminopyrimidine derivatives as lrrk2 modulators for use in the treatment of parkinson's disease |
| EP2961746B1 (en) | 2013-02-28 | 2018-01-03 | Bristol-Myers Squibb Company | Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors |
| AR094929A1 (es) | 2013-02-28 | 2015-09-09 | Bristol Myers Squibb Co | Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2 |
| ES2834430T3 (es) * | 2013-03-15 | 2021-06-17 | Univ Southern California | Procedimientos, compuestos y composiciones para el tratamiento de enfermedades relacionadas con la angiotensina |
| MA41179A (fr) | 2014-12-19 | 2017-10-24 | Cancer Research Tech Ltd | Composés inhibiteurs de parg |
| CN104844526B (zh) * | 2015-04-16 | 2018-08-31 | 温州医科大学 | 一种4,6-嘧啶二胺类化合物及其制备方法和应用 |
| CN106008366A (zh) * | 2016-05-25 | 2016-10-12 | 山东大学 | 一种利匹韦林的制备方法 |
| JP6165373B1 (ja) * | 2017-02-24 | 2017-07-19 | タマ化学工業株式会社 | ピリジン−３−スルホニルクロリドの製造方法 |
| EP3630291B9 (en) * | 2017-05-26 | 2024-05-29 | Cancer Research Technology Limited | Benzimidazolone derived inhibitors of bcl6 |
| IL296734B2 (en) | 2018-04-13 | 2025-06-01 | The Institute Of Cancer Res Royal Cancer Hospital | Bcl6 inhibitors |
| CN108864052A (zh) * | 2018-06-07 | 2018-11-23 | 福建医科大学 | 一种针对gc33-3-1抗体具有特异性识别的荧光探针的合成以及应用 |
| GB201914860D0 (en) | 2019-10-14 | 2019-11-27 | Cancer Research Tech Ltd | Inhibitor compounds |
| EP4206196A1 (en) * | 2021-12-29 | 2023-07-05 | Almirall S.A. | Pyrimidine substituted derivatives as tyk2 inhibitors |
| WO2023196714A2 (en) * | 2022-02-23 | 2023-10-12 | President And Fellows Of Harvard College | Inhibitors of ddr1 and ddr2 for the treatment of arthritis |
| PL4496795T3 (pl) | 2022-03-23 | 2026-07-20 | Ideaya Biosciences, Inc. | Związki indazolowe podstawione piperazyną jako inhibitory parg |
| US11891362B1 (en) * | 2023-04-14 | 2024-02-06 | King Faisal University | N2,N4-disubstituted pyrimidine-2,4-diamine compounds as antibacterial agents |
| JP2026520429A (ja) * | 2023-05-23 | 2026-06-23 | クオントエックス バイオサイエンシーズ ユーエス， インコーポレイテッド | 二環式ヘテロアリール化合物 |
| WO2024250010A2 (en) * | 2023-06-02 | 2024-12-05 | Atomwise Inc. | Inhibitors of tyk2 |
| WO2024249831A2 (en) * | 2023-06-02 | 2024-12-05 | Unogen Biotech Ltd. | Triple kinase inhibitors |
| WO2025096550A1 (en) * | 2023-10-31 | 2025-05-08 | Twine Therapeutics, Inc. | Methods of treating cardiomyopathy |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW504510B (en) * | 1996-05-10 | 2002-10-01 | Janssen Pharmaceutica Nv | 2,4-diaminopyrimidine derivatives |
| AU2002316421B2 (en) * | 2001-06-26 | 2008-05-15 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of TNF-ALPHA expression |
| WO2004087707A1 (en) * | 2003-03-31 | 2004-10-14 | Vernalis (Cambridge) Limited | Pyrazolopyrimidine compounds and their use in medicine |
| US8084457B2 (en) * | 2003-09-15 | 2011-12-27 | Lead Discovery Center Gmbh | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
| BRPI0506839A (pt) * | 2004-01-16 | 2007-06-12 | Novartis Ag | composições e métodos para induzir a cardiomiogênese |
| US20080242681A1 (en) * | 2004-01-22 | 2008-10-02 | Altana Pharma Ag | N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors |
| US20070203161A1 (en) * | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| UA109411C2 (uk) * | 2005-11-01 | 2015-08-25 | N-трет-бутил-3-(2-хлор-5-метилпіримідин-4-іламіно)бензолсульфонамід та його застосування в способі одержання сполуки | |
| WO2007053452A1 (en) * | 2005-11-01 | 2007-05-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| AU2007257650A1 (en) * | 2006-06-15 | 2007-12-21 | Boehringer Ingelheim International Gmbh | 2-anilino-4-(heterocyclic)amino-pyrimidines as inhibitors of protein kinase C-alpha |
| CN101589036A (zh) * | 2006-12-19 | 2009-11-25 | 沃泰克斯药物股份有限公司 | 可用作蛋白激酶抑制剂的氨基嘧啶 |
| US7947698B2 (en) * | 2007-03-23 | 2011-05-24 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
| EP2014657A1 (de) * | 2007-06-21 | 2009-01-14 | Bayer Schering Pharma Aktiengesellschaft | Diaminopyrimidine als Modulatoren des EP2-Rezeptors |
| JP5600063B2 (ja) * | 2007-10-19 | 2014-10-01 | セルジーン アビロミクス リサーチ， インコーポレイテッド | ヘテロアリール化合物およびその使用 |
-
2011
- 2011-01-11 CN CN2011800138247A patent/CN102791131A/zh active Pending
- 2011-01-11 BR BR112012017277A patent/BR112012017277A2/pt not_active IP Right Cessation
- 2011-01-11 CA CA2786999A patent/CA2786999A1/en not_active Abandoned
- 2011-01-11 EP EP11733258.5A patent/EP2523559A4/en not_active Withdrawn
- 2011-01-11 KR KR1020127021083A patent/KR20120114355A/ko not_active Withdrawn
- 2011-01-11 AU AU2011205485A patent/AU2011205485B2/en not_active Expired - Fee Related
- 2011-01-11 MX MX2012008141A patent/MX2012008141A/es unknown
- 2011-01-11 WO PCT/US2011/020798 patent/WO2011088027A1/en not_active Ceased
- 2011-01-11 US US13/520,861 patent/US20120329784A1/en not_active Abandoned
- 2011-01-11 SG SG2012049409A patent/SG182351A1/en unknown
- 2011-01-11 JP JP2012549000A patent/JP2013517273A/ja active Pending
- 2011-01-11 EA EA201290642A patent/EA201290642A1/ru unknown
-
2012
- 2012-07-05 IL IL220812A patent/IL220812A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20120329784A1 (en) | 2012-12-27 |
| WO2011088027A8 (en) | 2012-08-30 |
| SG182351A1 (en) | 2012-08-30 |
| AU2011205485B2 (en) | 2014-09-25 |
| KR20120114355A (ko) | 2012-10-16 |
| JP2013517273A (ja) | 2013-05-16 |
| MX2012008141A (es) | 2012-08-03 |
| EP2523559A1 (en) | 2012-11-21 |
| CN102791131A (zh) | 2012-11-21 |
| EA201290642A1 (ru) | 2013-05-30 |
| WO2011088027A1 (en) | 2011-07-21 |
| BR112012017277A2 (pt) | 2017-10-03 |
| AU2011205485A1 (en) | 2012-08-02 |
| CA2786999A1 (en) | 2011-07-21 |
| EP2523559A4 (en) | 2013-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL220939A0 (en) | Compounds and methods | |
| EP2523664A4 (en) | COMPOUNDS AND METHODS | |
| AP3107A (en) | 5-Alkynyl-pyrimidines | |
| EP2523559A4 (en) | COMPOUNDS AND METHODS | |
| IL226904A (en) | Inganol-3-acetylates iii and Inganol-3-carbamates | |
| GB201010196D0 (en) | Methods | |
| EP2736330A4 (en) | COMPOUNDS AND METHODS | |
| EP2747560A4 (en) | CONNECTIONS AND METHODS | |
| EP2736332A4 (en) | CONNECTIONS AND METHODS | |
| EP2736329A4 (en) | COMPOUNDS AND METHODS | |
| LT2531518T (lt) | Oligopeptidiniai dariniai ir jų panaudojimas | |
| EP2523560A4 (en) | CONNECTIONS AND METHODS | |
| ZA201303773B (en) | Compounds and their use | |
| GB201007944D0 (en) | Methods | |
| GB201002409D0 (en) | Methods | |
| GB201004450D0 (en) | Compounds and methods relating thereto | |
| SG10201508549UA (en) | Modified tamavidin | |
| GB201011367D0 (en) | Methods | |
| GB201015567D0 (en) | Methods | |
| GB201011010D0 (en) | Methods | |
| GB201001384D0 (en) | Light-fitting and associated methods | |
| GB201014319D0 (en) | Compounds and uses thereof | |
| GB201022060D0 (en) | Methods | |
| GB201000302D0 (en) | Methods | |
| GB201020854D0 (en) | Methods |